Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

— Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran —


— Acceptable Safety Profile Supporting Further Development —

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Simon Fox ,Akshay Desai ,Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Nasdaq ,Zilebesiran Program Lead At Alnylam ,Journal Of The American College Cardiology ,Securities Exchange ,Heart Failure Program ,Alnylam Pharmaceuticals Inc ,Nasdaq ,Health Promotion Series ,Instagram ,Exchange Commission ,Novartis ,Linkedin ,World Health Organization ,New England Journal ,Therapeutic Agent ,Advanced Heart Disease Section ,Cardiovascular Division ,Vice President ,Zilebesiran Program Lead ,Renin Angiotensin Aldosterone System ,Enhanced Stabilization Chemistry Plus ,Nobel Prize Winning ,Securities Act ,Securities Exchange Act ,Quarterly Reports ,World Health ,Published September ,American College ,Markets ,